Featured Research

from universities, journals, and other organizations

Fighting neuroblastomas by blocking DNA replication, repair

Date:
April 16, 2014
Source:
City of Hope
Summary:
PCNA is a protein essential to DNA repair and replication, and researchers are targeting it in neuroblastoma cells in order to halt tumor growth and induce cell death. Neuroblastoma is one of the deadliest childhood cancers, accounting for 15 percent of pediatric cancer deaths. For patients with high-risk neuroblastomas, the five-year survival rate is 40 to 50 percent even with the most rigorous treatments available today.

Neuroblastoma is one of the deadliest childhood cancers, accounting for 15 percent of pediatric cancer deaths. For patients with high-risk neuroblastomas, the five-year survival rate is 40 to 50 percent even with the most rigorous treatments available today.

But those odds may improve soon, thanks to a new compound developed by City of Hope scientists. The compound -- a peptide called R9-caPep -- works by targeting and disrupting proliferating cell nuclear antigens (PCNA), proteins that are essential in DNA synthesis, replication and repair.

The findings were published in PLoS ONE on April 11.

"We have previously reported identifying a subset of PCNAs that are expressed only in cancer cells," said Long Gu, Ph.D., assistant research professor in City of Hope's Department of Molecular and Cellular Biology and first author of the paper. "So we wanted to see if it's possible to single out and inhibit these cancer-associated PCNAs with this peptide, which would mean it's possible to deliver targeted therapy to malignant cells while leaving normal tissues unharmed."

In the study, Gu and his colleagues built R9-caPep to correspond to cancer-associated PCNAs. They then applied it to several neuroblastoma cell cultures. In their observations, they noted that R9-caPep successfully blocked PCNA actions in neuroblastoma cells with much less toxicity in noncancerous cells.

R9-caPep's interference with PCNA in cancer cells led to inhibition of their DNA replication and repair abilities, as well as inducing cell death. R9-caPep also made the neuroblastoma cells more sensitive to cisplatin, a cancer drug that works by damaging DNA.

These findings were further confirmed with animal trials. In this part of the study, Gu's team found that mice who were administered R9-caPep had almost no tumor growth, whereas the tumors in the control groups nearly tripled in volume and approximately doubled in mass over 25 days.

Additionally, the researchers found that R9-caPep was particularly effective on cancer cells with an amplified MYCN gene, which is linked to more aggressive and higher-risk neuroblastomas.

Given these promising findings, Gu and his team are currently conducting further studies to determine how R9-caPep disrupts DNA replication and repair in neuroblastoma cells. They will also be testing this and other peptides' therapeutic potential on breast, lung and pancreatic cancer cells.


Story Source:

The above story is based on materials provided by City of Hope. Note: Materials may be edited for content and length.


Journal Reference:

  1. Long Gu, Shanna Smith, Caroline Li, Robert J. Hickey, Jeremy M. Stark, Gregg B. Fields, Walter H. Lang, John A. Sandoval, Linda H. Malkas. A PCNA-Derived Cell Permeable Peptide Selectively Inhibits Neuroblastoma Cell Growth. PLoS ONE, 2014; 9 (4): e94773 DOI: 10.1371/journal.pone.0094773

Cite This Page:

City of Hope. "Fighting neuroblastomas by blocking DNA replication, repair." ScienceDaily. ScienceDaily, 16 April 2014. <www.sciencedaily.com/releases/2014/04/140416101339.htm>.
City of Hope. (2014, April 16). Fighting neuroblastomas by blocking DNA replication, repair. ScienceDaily. Retrieved August 20, 2014 from www.sciencedaily.com/releases/2014/04/140416101339.htm
City of Hope. "Fighting neuroblastomas by blocking DNA replication, repair." ScienceDaily. www.sciencedaily.com/releases/2014/04/140416101339.htm (accessed August 20, 2014).

Share This




More Health & Medicine News

Wednesday, August 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Freetown a City on Edge

Ebola-Hit Sierra Leone's Freetown a City on Edge

AFP (Aug. 19, 2014) Residents of Sierra Leone's capital voice their fears as the Ebola virus sweeps through west Africa. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com
101-Year-Old Working Man Has All The Advice You Need

101-Year-Old Working Man Has All The Advice You Need

Newsy (Aug. 19, 2014) Herman Goldman has worked at the same lighting store for almost 75 years. Find out his secrets to a happy, productive life. Video provided by Newsy
Powered by NewsLook.com
Researcher Testing on-Field Concussion Scanners

Researcher Testing on-Field Concussion Scanners

AP (Aug. 19, 2014) Four Texas high school football programs are trying out an experimental system designed to diagnose concussions on the field. The technology is in response to growing concern over head trauma in America's most watched sport. (Aug. 19) Video provided by AP
Powered by NewsLook.com
American Ebola Patient Apparently Improving, Outbreak Is Not

American Ebola Patient Apparently Improving, Outbreak Is Not

Newsy (Aug. 19, 2014) Nancy Writebol, an American missionary who contracted Ebola, is apparently getting better, according to her husband. The outbreak, however, is not. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins